Untangling Nonerosive Reflux Disease From Functional Heartburn

Vakil, 2006, The Montreal definition and classification of gastroesophageal reflux disease: a global evidence-based consensus, Am J Gastroenterol, 101, 1900, 10.1111/j.1572-0241.2006.00630.x Gyawali, 2018, Modern diagnosis of GERD: the Lyon Consensus, Gut, 67, 1351, 10.1136/gutjnl-2017-314722 Modlin, 2009, Diagnosis and management of non-erosive reflux disease--the Vevey NERD Consensus Group, Digestion, 80, 74, 10.1159/000219365 Clouse, 1999, Functional esophageal disorders, Gut, 45, II31 Drossman, 2000 Fass, 2005, Systematic review: proton-pump inhibitor failure in gastro-oesophageal reflux disease--where next?, Aliment Pharmacol Ther, 22, 79, 10.1111/j.1365-2036.2005.02531.x Drossman, 2016, Functional gastrointestinal disorders: history, pathophysiology, clinical features and Rome IV, Gastroenterology, 10.1053/j.gastro.2016.02.032 Eusebi, 2018, Global prevalence of, and risk factors for, gastro-oesophageal reflux symptoms: a meta-analysis, Gut, 67, 430, 10.1136/gutjnl-2016-313589 El-Serag, 2014, Update on the epidemiology of gastro-oesophageal reflux disease: a systematic review, Gut, 63, 871, 10.1136/gutjnl-2012-304269 Martinez, 2003, Non-erosive reflux disease (NERD)--acid reflux and symptom patterns, Aliment Pharmacol Ther, 17, 537, 10.1046/j.1365-2036.2003.01423.x Quigley, 2006, Non-erosive reflux disease, functional heartburn and gastroesophageal reflux disease; insights into pathophysiology and clinical presentation, Chin J Dig Dis, 7, 186, 10.1111/j.1443-9573.2006.00266.x Tefera, 1997, Can the combination of symptoms and endoscopy confirm the presence of gastroesophageal reflux disease?, Am Surg, 63, 933 Johansson, 1986, Oesophagitis, signs of reflux, and gastric acid secretion in patients with symptoms of gastro-oesophageal reflux disease, Scand J Gastroenterol, 21, 837, 10.3109/00365528609011128 Ronkainen, 2005, High prevalence of gastroesophageal reflux symptoms and esophagitis with or without symptoms in the general adult Swedish population: a Kalixanda study report, Scand J Gastroenterol, 40, 275, 10.1080/00365520510011579 Zagari, 2008, Gastro-oesophageal reflux symptoms, oesophagitis and Barrett's oesophagus in the general population: the Loiano-Monghidoro study, Gut, 57, 1354, 10.1136/gut.2007.145177 Fass, 2007, Erosive esophagitis and nonerosive reflux disease (NERD): comparison of epidemiologic, physiologic, and therapeutic characteristics, J Clin Gastroenterol, 41, 131, 10.1097/01.mcg.0000225631.07039.6d Yamasaki, 2017, Reflux hypersensitivity: a new functional esophageal disorder, J Neurogastroenterol Motil, 23, 495, 10.5056/jnm17097 Fullard, 2006, Systematic review: does gastro-oesophageal reflux disease progress?, Aliment Pharmacol Ther, 24, 33, 10.1111/j.1365-2036.2006.02963.x Labenz, 2006, Prospective follow-up data from the ProGERD study suggest that GERD is not a categorial disease, Am J Gastroenterol, 101, 2457, 10.1111/j.1572-0241.2006.00829.x Surdea Blaga, 2013, Functional heartburn: clinical characteristics and outcome, Eur J Gastroenterol Hepatol, 25, 282, 10.1097/MEG.0b013e32835b108f Zerbib, 2012, Functional heartburn: definition and management strategies, Curr Gastroenterol Rep, 14, 181, 10.1007/s11894-012-0255-7 Knowles, 2008, Visceral hypersensitivity in non-erosive reflux disease, Gut, 57, 674, 10.1136/gut.2007.127886 Bredenoord, 2006, Characteristics of gastroesophageal reflux in symptomatic patients with and without excessive esophageal acid exposure, Am J Gastroenterol, 101, 2470, 10.1111/j.1572-0241.2006.00945.x Emerenziani, 2008, Presence of gas in the refluxate enhances reflux perception in non-erosive patients with physiological acid exposure of the oesophagus, Gut, 57, 443, 10.1136/gut.2007.130104 Frazzoni, 2004, Pathophysiological characteristics of patients with non-erosive reflux disease differ from those of patients with functional heartburn, Aliment Pharmacol Ther, 20, 81, 10.1111/j.1365-2036.2004.01998.x Yang, 2010, Quantitative assessment and characterization of visceral hyperalgesia evoked by esophageal balloon distention and acid perfusion in patients with functional heartburn, nonerosive reflux disease, and erosive esophagitis, Clin J Pain, 26, 326, 10.1097/AJP.0b013e3181c8fc83 Hobson, 2008, Oesophageal afferent pathway sensitivity in non-erosive reflux disease, Neurogastroenterol Motil, 20, 877, 10.1111/j.1365-2982.2008.01122.x Thoua, 2008, Acid-related oesophageal sensitivity, not dysmotility, differentiates subgroups of patients with non-erosive reflux disease, Aliment Pharmacol Ther, 27, 396, 10.1111/j.1365-2036.2007.03584.x Klauser, 1989, Is long-term esophageal pH monitoring of clinical value?, Am J Gastroenterol, 84, 362 DeMeester, 1980, Technique, indications, and clinical use of 24 hour esophageal pH monitoring, J Thorac Cardiovasc Surg, 79, 656, 10.1016/S0022-5223(19)37879-1 Fass, 2009, Functional heartburn: what it is and how to treat it, Gastrointest Endosc Clin N Am, 19, 23, 10.1016/j.giec.2008.12.002 Hershcovici, 2008, Functional heartburn vs. non-erosive reflux disease: similarities and differences, Aliment Pharmacol Ther, 27, 1103, 10.1111/j.1365-2036.2008.03666.x Shapiro, 2006, Functional heartburn patients demonstrate traits of functional bowel disorder but lack a uniform increase of chemoreceptor sensitivity to acid, Am J Gastroenterol, 101, 1084, 10.1111/j.1572-0241.2006.00525.x Savarino, 2009, Functional heartburn has more in common with functional dyspepsia than with non-erosive reflux disease, Gut, 58, 1185, 10.1136/gut.2008.175810 de Bortoli, 2016, Functional heartburn overlaps with irritable bowel syndrome more often than GERD, Am J Gastroenterol, 111, 1711, 10.1038/ajg.2016.432 Hershcovici, 2010, GERD: are functional heartburn and functional dyspepsia one disorder?, Nat Rev Gastroenterol Hepatol, 7, 71, 10.1038/nrgastro.2009.233 Dent, 2007, Microscopic esophageal mucosal injury in nonerosive reflux disease, Clin Gastroenterol Hepatol, 5, 4, 10.1016/j.cgh.2006.08.006 Fiocca, 2010, Development of consensus guidelines for the histologic recognition of microscopic esophagitis in patients with gastroesophageal reflux disease: the Esohisto project, Hum Pathol, 41, 223, 10.1016/j.humpath.2009.07.016 Yerian, 2011, Refinement and reproducibility of histologic criteria for the assessment of microscopic lesions in patients with gastroesophageal reflux disease: the Esohisto Project, Dig Dis Sci, 56, 2656, 10.1007/s10620-011-1624-z Savarino, 2013, Microscopic esophagitis distinguishes patients with non-erosive reflux disease from those with functional heartburn, J Gastroenterol, 48, 473, 10.1007/s00535-012-0672-2 Kandulski, 2013, Histomorphological differentiation of non-erosive reflux disease and functional heartburn in patients with PPI-refractory heartburn, Aliment Pharmacol Ther, 38, 643, 10.1111/apt.12428 Madan, 2005, Impact of 24-h esophageal pH monitoring on the diagnosis of gastroesophageal reflux disease: defining the gold standard, J Gastroenterol Hepatol, 20, 30, 10.1111/j.1440-1746.2004.03530.x Sweis, 2011, Prolonged, wireless pH-studies have a high diagnostic yield in patients with reflux symptoms and negative 24-h catheter-based pH-studies, Neurogastroenterol Motil, 23, 419, 10.1111/j.1365-2982.2010.01663.x Penagini, 2015, Inconsistency in the diagnosis of functional heartburn: usefulness of prolonged wireless pH monitoring in patients with proton pump inhibitor refractory gastroesophageal reflux disease, J Neurogastroenterol Motil, 21, 265, 10.5056/jnm14075 Bautista, 2005, The value of ambulatory 24 hr esophageal pH monitoring in clinical practice in patients who were referred with persistent gastroesophageal reflux disease (GERD)-related symptoms while on standard dose anti-reflux medications, Dig Dis Sci, 50, 1909, 10.1007/s10620-005-2960-7 Vela, 2001, Simultaneous intraesophageal impedance and pH measurement of acid and nonacid gastroesophageal reflux: effect of omeprazole, Gastroenterology, 120, 1599, 10.1053/gast.2001.24840 Wiener, 1988, The symptom index: a clinically important parameter of ambulatory 24-hour esophageal pH monitoring, Am J Gastroenterol, 83, 358 Weusten, 1994, The symptom-association probability: an improved method for symptom analysis of 24-hour esophageal pH data, Gastroenterology, 107, 1741, 10.1016/0016-5085(94)90815-X Singh, 1993, The symptom index. Differential usefulness in suspected acid-related complaints of heartburn and chest pain, Dig Dis Sci, 38, 1402, 10.1007/BF01308595 Slaughter, 2011, Caution about overinterpretation of symptom indexes in reflux monitoring for refractory gastroesophageal reflux disease, Clin Gastroenterol Hepatol, 9, 868, 10.1016/j.cgh.2011.07.009 Kavitt, 2012, Symptom reports are not reliable during ambulatory reflux monitoring, Am J Gastroenterol, 107, 1826, 10.1038/ajg.2012.342 Savarino, 2008, The role of nonacid reflux in NERD: lessons learned from impedance-pH monitoring in 150 patients off therapy, Am J Gastroenterol, 103, 2685, 10.1111/j.1572-0241.2008.02119.x Roman, 2017, Ambulatory reflux monitoring for diagnosis of gastro-esophageal reflux disease: update of the Porto consensus and recommendations from an international consensus group, Neurogastroenterol Motil, 29, 1, 10.1111/nmo.13067 de Bortoli, 2015, Association between baseline impedance values and response proton pump inhibitors in patients with heartburn, Clin Gastroenterol Hepatol, 13, 1082, 10.1016/j.cgh.2014.11.035 Frazzoni, 2016, Analyses of the post-reflux swallow-induced peristaltic wave index and nocturnal baseline impedance parameters increase the diagnostic yield of impedance-pH monitoring of patients with reflux disease, Clin Gastroenterol Hepatol, 14, 40, 10.1016/j.cgh.2015.06.026 Frazzoni, 2017, Impairment of chemical clearance and mucosal integrity distinguishes hypersensitive esophagus from functional heartburn, J Gastroenterol, 52, 444, 10.1007/s00535-016-1226-9 Martinucci, 2014, Esophageal baseline impedance levels in patients with pathophysiological characteristics of functional heartburn, Neurogastroenterol Motil, 26, 546, 10.1111/nmo.12299 Frazzoni, 2014, Impairment of chemical clearance is relevant to the pathogenesis of refractory reflux oesophagitis, Dig Liver Dis, 46, 596, 10.1016/j.dld.2014.03.005 Frazzoni, 2017, Postreflux swallow-induced peristaltic wave index and nocturnal baseline impedance can link PPI-responsive heartburn to reflux better than acid exposure time, Neurogastroenterol Motil, 29, 10.1111/nmo.13116 Farre, 2011, Evaluation of oesophageal mucosa integrity by the intraluminal impedance technique, Gut, 60, 885, 10.1136/gut.2010.233049 Kessing, 2011, Esophageal acid exposure decreases intraluminal baseline impedance levels, Am J Gastroenterol, 106, 2093, 10.1038/ajg.2011.276 Kandulski, 2015, Esophageal intraluminal baseline impedance differentiates gastroesophageal reflux disease from functional heartburn, Clin Gastroenterol Hepatol, 13, 1075, 10.1016/j.cgh.2014.11.033 Zhong, 2013, Esophageal intraluminal baseline impedance is associated with severity of acid reflux and epithelial structural abnormalities in patients with gastroesophageal reflux disease, J Gastroenterol, 48, 601, 10.1007/s00535-012-0689-6 Woodland, 2013, In vivo evaluation of acid-induced changes in oesophageal mucosa integrity and sensitivity in non-erosive reflux disease, Gut, 62, 1256, 10.1136/gutjnl-2012-302645 Patel, 2016, Distal mean nocturnal baseline impedance on pH-impedance monitoring predicts reflux burden and symptomatic outcome in gastro-oesophageal reflux disease, Aliment Pharmacol Ther, 44, 890, 10.1111/apt.13777 van Rhijn, 2014, Proton pump inhibitors partially restore mucosal integrity in patients with proton pump inhibitor-responsive esophageal eosinophilia but not eosinophilic esophagitis, Clin Gastroenterol Hepatol, 12, 1815, 10.1016/j.cgh.2014.02.037 Rinsma, 2015, The effect of endoscopic fundoplication and proton pump inhibitors on baseline impedance and heartburn severity in GERD patients, Neurogastroenterol Motil, 27, 220, 10.1111/nmo.12468 Gyawali, 2017, Classification of esophageal motor findings in gastro-esophageal reflux disease: conclusions from an international consensus group, Neurogastroenterol Motil, 29, 10.1111/nmo.13104 Pandolfino, 2007, High-resolution manometry of the EGJ: an analysis of crural diaphragm function in GERD, Am J Gastroenterol, 102, 1056, 10.1111/j.1572-0241.2007.01138.x Kahrilas, 2015, The Chicago Classification of esophageal motility disorders, v3.0, Neurogastroenterol Motil, 27, 160, 10.1111/nmo.12477 Tolone, 2015, Esophagogastric junction morphology is associated with a positive impedance-pH monitoring in patients with GERD, Neurogastroenterol Motil, 27, 1175, 10.1111/nmo.12606 Ham, 2017, Esophagogastric junction contractile integral and morphology: two high-resolution manometry metrics of the anti-reflux barrier, J Gastroenterol Hepatol, 32, 1443, 10.1111/jgh.13720 Tolone, 2015, Esophagogastric junction contractility for clinical assessment in patients with GERD: a real added value?, Neurogastroenterol Motil, 27, 1423, 10.1111/nmo.12638 Jasper, 2017, Prolonged measurement improves the assessment of the barrier function of the esophago-gastric junction by high-resolution manometry, Neurogastroenterol Motil, 29, 10.1111/nmo.12925 Wang, 2016, Esophagogastric junction contractile integral (EGJ-CI) quantifies changes in EGJ barrier function with surgical intervention, Neurogastroenterol Motil, 28, 639, 10.1111/nmo.12757 Ho, 2002, Ineffective esophageal motility is a primary motility disorder in gastroesophageal reflux disease, Dig Dis Sci, 47, 652, 10.1023/A:1017992808762 Diener, 2001, Esophageal dysmotility and gastroesophageal reflux disease, J Gastrointest Surg, 5, 260, 10.1016/S1091-255X(01)80046-9 Meneghetti, 2005, Esophageal mucosal damage may promote dysmotility and worsen esophageal acid exposure, J Gastrointest Surg, 9, 1313, 10.1016/j.gassur.2005.08.033 Savarino, 2011, Oesophageal motility and bolus transit abnormalities increase in parallel with the severity of gastro-oesophageal reflux disease, Aliment Pharmacol Ther, 34, 476, 10.1111/j.1365-2036.2011.04742.x Ribolsi, 2012, Impedance baseline and reflux perception in responder and non-responder non-erosive reflux disease patients, Scand J Gastroenterol, 47, 1266, 10.3109/00365521.2012.722674 Ates, 2015, Mucosal impedance discriminates GERD from non-GERD conditions, Gastroenterology, 148, 334, 10.1053/j.gastro.2014.10.010 Patel, 2017, Utility of esophageal mucosal impedance as a diagnostic test for esophageal disease, Curr Opin Gastroenterol, 33, 277, 10.1097/MOG.0000000000000367 Katzka, 2015, Endoscopic mucosal impedance measurements correlate with eosinophilia and dilation of intercellular spaces in patients with eosinophilic esophagitis, Clin Gastroenterol Hepatol, 13, 1242, 10.1016/j.cgh.2014.12.032 Barrett, 2019, Tu1173 – esophageal mucosal integrity is unchanged in patients with functional heartburn and reflux hypersensitivity, Gastroenterology, 156, S-971, 10.1016/S0016-5085(19)39383-7 Patel, 2019, Development and validation of a mucosal impedance contour analysis system to distinguish esophageal disorders, Gastroenterology, 156, 1617, 10.1053/j.gastro.2019.01.253 Sabesin, 1991, Famotidine relieves symptoms of gastroesophageal reflux disease and heals erosions and ulcerations. Results of a multicenter, placebo-controlled, dose-ranging study. USA Merck Gastroesophageal Reflux Disease Study Group, Arch Intern Med, 151, 2394, 10.1001/archinte.1991.00400120040007 Hatlebakk, 1997, The effect of cisapride in maintaining symptomatic remission in patients with gastro-oesophageal reflux disease, Scand J Gastroenterol, 32, 1100, 10.3109/00365529709002988 Dean, 2004, Effectiveness of proton pump inhibitors in nonerosive reflux disease, Clin Gastroenterol Hepatol, 2, 656, 10.1016/S1542-3565(04)00288-5 Fenton, 2000, Is there a role for laparoscopic fundoplication in patients with non-erosive reflux disease (NERD)?, Gastroenterology, 118, A481, 10.1016/S0016-5085(00)84041-X Park, 2017, Factors predicting outcomes of laparoscopic Nissen fundoplication for gastroesophageal reflux disease: experience at a single institution in Korea, Ann Surg Treat Res, 92, 184, 10.4174/astr.2017.92.4.184 Kamolz, 2003, The outcome of laparoscopic antireflux surgery in relation to patients' subjective degree of compliance with former antireflux medication, Surg Laparosc Endosc Percutan Tech, 13, 155, 10.1097/00129689-200306000-00003 Campos, 1999, Multivariate analysis of factors predicting outcome after laparoscopic Nissen fundoplication, J Gastrointest Surg, 3, 292, 10.1016/S1091-255X(99)80071-7 Hamdy, 2014, Outcome of laparoscopic Nissen fundoplication for gastroesophageal reflux disease in non-responders to proton pump inhibitors, J Gastrointest Surg, 18, 1557, 10.1007/s11605-014-2584-3 Tolone, 2016, Pre-operative clinical and instrumental factors as antireflux surgery outcome predictors, World J Gastrointest Surg, 8, 719, 10.4240/wjgs.v8.i11.719 Rothstein, 2006, Endoscopic full-thickness plication for the treatment of gastroesophageal reflux disease: a randomized, sham-controlled trial, Gastroenterology, 131, 704, 10.1053/j.gastro.2006.07.004 Arts, 2012, A double-blind sham-controlled study of the effect of radiofrequency energy on symptoms and distensibility of the gastro-esophageal junction in GERD, Am J Gastroenterol, 107, 222, 10.1038/ajg.2011.395 Hunter, 2015, Efficacy of transoral fundoplication vs omeprazole for treatment of regurgitation in a randomized controlled trial, Gastroenterology, 148, 324, 10.1053/j.gastro.2014.10.009 Pandolfino, 2014, Do endoscopic antireflux procedures fit in the current treatment paradigm of gastroesophageal reflux disease?, Clin Gastroenterol Hepatol, 12, 544, 10.1016/j.cgh.2013.06.012 Bell, 2020, Magnetic sphincter augmentation superior to proton pump inhibitors for regurgitation in a 1-year randomized trial, Clin Gastroenterol Hepatol, 18, 1736, 10.1016/j.cgh.2019.08.056 Richter, 2018, Efficacy of laparoscopic Nissen fundoplication vs transoral incisionless fundoplication or proton pump inhibitors in patients with gastroesophageal reflux disease: a systematic review and network meta-analysis, Gastroenterology, 154, 1298, 10.1053/j.gastro.2017.12.021 Kaindlstorfer, 2013, A randomized trial on endoscopic full-thickness gastroplication versus laparoscopic antireflux surgery in GERD patients without hiatal hernias, Surg Laparosc Endosc Percutan Tech, 23, 212, 10.1097/SLE.0b013e3182827f79 Scarpignato, 2013, Poor effectiveness of PPIs in non-erosive reflux disease: the truth in the end!, Neurogastroenterol Motil, 25, 707, 10.1111/nmo.12166 Johnston, 1995, Acid perception in gastro-oesophageal reflux disease is dependent on psychosocial factors, Scand J Gastroenterol, 30, 1, 10.3109/00365529509093228 Lind, 1997, Heartburn without oesophagitis: efficacy of omeprazole therapy and features determining therapeutic response, Scand J Gastroenterol, 32, 974, 10.3109/00365529709011212 Zerbib, 2012, Clinical, but not oesophageal pH-impedance, profiles predict response to proton pump inhibitors in gastro-oesophageal reflux disease, Gut, 61, 501, 10.1136/gutjnl-2011-300798 Rodriguez-Stanley, 2004, A single dose of ranitidine 150 mg modulates oesophageal acid sensitivity in patients with functional heartburn, Aliment Pharmacol Ther, 20, 975, 10.1111/j.1365-2036.2004.02217.x Khajanchee, 2004, Outcomes of antireflux surgery in patients with normal preoperative 24-hour pH test results, Am J Surg, 187, 599, 10.1016/j.amjsurg.2004.01.010 Weijenborg, 2015, Effects of antidepressants in patients with functional esophageal disorders or gastroesophageal reflux disease: a systematic review, Clin Gastroenterol Hepatol, 13, 251, 10.1016/j.cgh.2014.06.025 Dickman, 2014, The role of pain modulators in esophageal disorders - no pain no gain, Neurogastroenterol Motil, 26, 603, 10.1111/nmo.12339 George, 2016, Review article: the current treatment of non-cardiac chest pain, Aliment Pharmacol Ther, 43, 213, 10.1111/apt.13458 Gyawali, 2018, Management of gastroesophageal reflux disease, Gastroenterology, 154, 302, 10.1053/j.gastro.2017.07.049 Krarup, 2011, Randomised clinical trial: the efficacy of a transient receptor potential vanilloid 1 antagonist AZD1386 in human oesophageal pain, Aliment Pharmacol Ther, 33, 1113, 10.1111/j.1365-2036.2011.04629.x Krarup, 2013, Randomized clinical trial: inhibition of the TRPV1 system in patients with nonerosive gastroesophageal reflux disease and a partial response to PPI treatment is not associated with analgesia to esophageal experimental pain, Scand J Gastroenterol, 48, 274, 10.3109/00365521.2012.758769 Riehl, 2016, Feasibility and acceptability of esophageal-directed hypnotherapy for functional heartburn, Dis Esophagus, 29, 490, 10.1111/dote.12353 Dickman, 2007, Clinical trial: acupuncture vs. doubling the proton pump inhibitor dose in refractory heartburn, Aliment Pharmacol Ther, 26, 1333, 10.1111/j.1365-2036.2007.03520.x Hachem, 2016, Diagnosis and management of functional heartburn, Am J Gastroenterol, 111, 53, 10.1038/ajg.2015.376 Cannon, 1994, Imipramine in patients with chest pain despite normal coronary angiograms, N Engl J Med, 330, 1411, 10.1056/NEJM199405193302003 Cox, 1998, Low dose imipramine improves chest pain but not quality of life in patients with angina and normal coronary angiograms, Eur Heart J, 19, 250, 10.1053/euhj.1997.0615 Marsden, 2016, Imipramine for treatment of esophageal hypersensitivity and functional heartburn, Am J Gastroenterol, 111, 1358, 10.1038/ajg.2016.160 Park, 2013, Low-dose amitriptyline combined with proton pump inhibitor for functional chest pain, World J Gastroenterol, 19, 4958, 10.3748/wjg.v19.i30.4958 You, 2013, Effect of low-dose amitriptyline on globus pharyngeus and its side effects, World J Gastroenterol, 19, 7455, 10.3748/wjg.v19.i42.7455 Lee, 2010, Efficacy of venlafaxine for symptomatic relief in young adult patients with functional chest pain: a randomized, double-blind, placebo-controlled, crossover trial, Am J Gastroenterol, 105, 1504, 10.1038/ajg.2010.82 Varia, 2000, Randomized trial of sertraline in patients with unexplained chest pain of noncardiac origin, Am Heart J, 140, 367, 10.1067/mhj.2000.108514 Keefe, 2011, Effects of coping skills training and sertraline in patients with non-cardiac chest pain: a randomized controlled study, Pain, 152, 730, 10.1016/j.pain.2010.08.040 Doraiswamy, 2006, A randomized controlled trial of paroxetine for noncardiac chest pain, Psychopharmacol Bull, 39, 15 Palsson, 2010, Heart-focused anxiety as a mediating variable in the treatment of non-cardiac chest pain by cognitive-behavioural and psychopharmacological treatment by paroxetine, J Psychosom Res, 69, 237, 10.1016/j.jpsychores.2010.04.016 Broekaert, 2006, Influence of citalopram, a selective serotonin reuptake inhibitor, on oesophageal hypersensitivity: a double-blind, placebo-controlled study, Aliment Pharmacol Ther, 23, 365, 10.1111/j.1365-2036.2006.02772.x Ostovaneh, 2014, Comparing omeprazole with fluoxetine for treatment of patients with heartburn and normal endoscopy who failed once daily proton pump inhibitors: double-blind placebo-controlled trial, Neurogastroenterol Motil, 26, 670, 10.1111/nmo.12313 Basu, 2014, The effect of melatonin in functional heartburn: a randomized, placebo-controlled clinical trial, Open J Gastroenterol, 4, 56, 10.4236/ojgas.2014.42010 Rao, 2007, Theophylline improves esophageal chest pain--a randomized, placebo-controlled study, Am J Gastroenterol, 102, 930, 10.1111/j.1572-0241.2007.01112.x Kirch, 2013, Globus pharyngeus: effectiveness of treatment with proton pump inhibitors and gabapentin, Ann Otol Rhinol Laryngol, 122, 492, 10.1177/000348941312200803